Lipocine
Update in progressLPCN (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Lipocine is a clinical-stage biopharmaceutical company developing oral drug delivery with its proprietary technology. Its focus includes neurological and psychiatric CNS disorders, liver disease, and hormone therapy. The lead product TLANDO is an oral testosterone replacement. Its pipeline includes LPCN 1154, 1148, 1107, 1144, 2401, 2201, 2203, and 2101 at various trial stages. Lipocine collaborates with Verity on TLANDO and TLANDO XR. Founded 1997, based in Salt Lake City, Utah.
Company score
- Sentiment
- 0.29
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.24
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Mahesh V. Patel Ph.D.
- Founded1997
- Employees14
- Websitewww.lipocine.com
Identifiers
- ISINUS53630X1046
- FIGIBBG0029L1X69
- LEI549300RXPEQXOJXVBI10
- CUSIP53630X104
- CIK0001535955